Week in Review: Hisun-Pfizer Inc. and Merck & Co., Inc.-Simcere Pharmaceutical Group JVs Come Into Focus
Published: May 28, 2013
by Richard Daverman, PhD
May 25, 2013 -- Zhejiang Hisun Pharma contributed 75 drug products to gain 51% control of its JV with Pfizer, while Pfizer added eight drugs; the Merck-Simcere JV is focused onsix cardiovascular drugs, two from Simcere and the rest from Merck; 3SBio’s shareholders voted to accept a go-private offer priced at $16.70 per ADS; Janssen Pharma, a division of Johnson & Johnson, has four new medical entities awaiting approval in China and expects to file an additional nine NMEs by 2017; GlaxoSmithKline cut the prices of its China drugs and watched revenues jump as a result; Zensun Sci & Tech, a Shanghai-San Diego biopharma, reported positive results from four Phase II trials of its heart failure drug, Neucardin™; the CFDA approved clinical trials of a novel AIDS treatment developed at Zhengzhou University; Curative Medical will oversee a China clinical trial for ALung’s respiratory medical device; and China’s bird flu crisis has been contained, according to UN officials. More details….
Stock Symbols: (SHA: 600267) (NYSE: PFE) (NYSE: MRK) (NYSE: SCR) (NSDQ: SSRX) (NYSE: JNJ) (NYSE: GSK)
Help employers find you! Check out all the jobs and post your resume.